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Abstract 
Positron emission tomography (PET) and fluorescence labelling have been used to assess the 
pharmacokinetics, biodistribution and eventual fate of a hydrogel-forming nonapeptide, 
FEFKFEFKK (F9) in healthy mice, using 
18
F-labelled and fluoresceinisothiocyanate (FITC) - 
labelled F9 analogues. F9 was site-specifically radiolabelled with 2-[
18
F]fluoro-3-
pyridinecarboxaldehyde ([
18
F]FPCA) via oxime bond formation. [
18
F]FPCA-F9 in vivo fate 
was evaluated both as a solution, following intravenous administration, and as a hydrogel 
when subcutaneously injected. The behaviour of FITC-F9 hydrogel was assessed following 
subcutaneous injection. [
18
F]FPCA-F9 demonstrated high plasma stability and primarily renal 
excretion; [
18
F]FPCA-F9 when in solution and injected into the bloodstream displayed 
prompt bladder uptake (53.4 ± 16.6 SUV at 20 minutes post injection) and rapid renal 
excretion, whereas [
18
F]FPCA-F9 hydrogel, formed by co-assembly of [
18
F]FPCA-F9 
monomer with unfunctionalised F9 peptide and injected subcutaneously, showed gradual 
bladder accumulation of hydrogel fragments (3.8 ± 0.4 SUV at 20 minutes post injection), 
resulting in slower renal excretion. Gradual disaggregation of the F9 hydrogel from the site of 
injection was monitored using FITC-F9 hydrogel in healthy mice (60 ± 3 over 96 hours), 
indicating a biological half-life between 1-4 days. The in vivo characterisation of F9, both as 
a gel and a solution highlights its potential as a biomaterial.  
Introduction 
The potential of peptide hydrogels as biomaterials is vast on account of their in vivo and in 
vitro potential uses in a variety of biomedical applications. These include their use as 
scaffolding for 3D cell cultures, tissues engineering and regenerative medicine as well as 
their use as vehicle for localised drug delivery 
[1-6]
. Peptide hydrogels are made of short 
synthetic peptides composed of either natural or non-natural amino acids that are designed to 
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self-assemble into higher biomimetic structures. This is achieved via non-covalent 
interactions in response to external triggers, such as pH, ionic strength, enzymes and light, to 
form three-dimensional networks of entangled fibrous structures 
[7, 8]
.  
In the present study, the in vivo behaviour of a β–sheet forming peptide FEFKFEFKK (F9) 
(F: phenylalanine; K: Lysine; E: glutamic acid) and its hydrogel was characterised. F9 is one 
of a family of amphipathic peptides with alternating hydrophobic and hydrophilic residues 
that self-assembles into β–sheet fibres that above a critical gelation concentration (CGC) 
associates to form a hydrogel. The properties of the hydrogels can be tailored through peptide 
design, concentration, media pH and ionic strength 
[9]
; as such they have been shown to hold 
promise for application in the biomedical field as 3D cell culture matrices 
[10]
 and/or drug 
delivery vehicles 
[5]
.  
Positron emission tomography (PET) is a quantitative imaging modality boasting high levels 
of sensitivity. The tool was used to assess the behaviour of radiolabelled F9 ([
18
F]FPCA-F9) 
in vivo using C3H mice. [
18
F]FPCA-F9 was first delivered as a solution (concentration below 
CGC, pH 5.6) into the tail-vein to study the fate of peptide monomer in the blood stream. 
Subsequently [
18
F]FPCA-F9 was delivered as part of an F9-hydrogel (concentration above 
CGC, pH 5.6) by co-assembly with unfunctionalised F9 peptide, before subcutaneous 
injection into the mouse flank.  
Site-specific radiolabelling of F9 was selected to safeguard the -sheet forming and therefore 
the gel-forming capability of the peptide. To achieve this, the N-terminal amine was 
functionalised with an amino(oxy)-group to give (Aoa)F9 (Mr 1338.59 Da). Functionalisation 
of the peptide with the amino(oxy)-moiety permits its radiolabelling with the 
18
F-prosthetic 
group 2-[
18
F]fluoro-3-pyridinecarboxaldehyde (FPCA) via oxime-bond formation, as has 
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previously been described 
[11]
. The radiosynthesis pathway of [
18
F]FPCA-F9 by 
radiolabelling of (Aoa)F9 with [
18
F]FPCA is shown in Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
PET studies were complemented by in vivo fluorescence imaging, making use of a 
fluoresceinisothiocyanate N-terminal labelled F9 peptide (FITC-F9). Fluorescence data 
provided information regarding the long term stability of the hydrogel, in healthy mice, over 
5 days; a time-frame outside the window of the radionuclidic half-life of 
18
F (110 minutes).   
Experimental 
All solvents were purchased from Sigma-Aldrich and used without further purification. 
(Aoa)F9 was purchased from Biomatik (Ontario, Canada) in trifluoroacetic acid (TFA) salt, 
 
 + 
 
(Aoa)-F9 [18F]FPCA 
[18F]FPCA-F9 
Figure 1: Reaction pathway showing (Aoa)F9 radiolabelling with [
18
F]FPCA 
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purity >98 %. FITC-F9 was purchased from Biomatik as a TFA salt (purity >98 %) and 
converted into the HCl salt of the peptide. [
18
F]Fluoride was produced onsite via the 
18
O(p, 
n)
18
F nuclear reaction by 16.4 MeV proton bombardment of enriched [
18
O]H2O using a GE 
PETtrace cyclotron (GE Healthcare, Sweden). Analytical HPLC was performed using a 
Shimadzu (Milton Keynes, UK) Prominence system (LC-20AB solvent delivery system, 
SPD-20A dual wavelength absorbance detector) controlled by LabLogic (Sheffield, UK), 
Laura 3 software via a CBM-20A controller. HPLC eluate was measured for radioactivity 
using a Bioscan (Oxford, UK) Flow-count B-FC 3100 gamma detector. All pre-clinical PET 
scans were carried out using a Siemens (Oxford, UK) Inveon® PET-CT scanner. 
Fluorescence in vivo imaging was carried out using a Biospace Lab Photon Imager Optima 
(Nesles-la-Valee, France) controlled by Biospace Lab Photo Acquisition software v3.4 and 
images analysed using Biospace Lab M3 Vision software. 
Radiochemistry 
 [
18
F]Potassium fluoride 
Cyclotron produced [
18
F]fluoride was delivered to a TRACERlab FX-FN radiochemistry 
system (GE Healthcare, UK) and trapped on a Sep-Pak QMA cartridge (Oasis, Waters, UK). 
The cartridge was then eluted with a K2CO3 solution (4 μmol, 0.4 mL) into a reactor 
containing 18-crown-6 (8 mg, 30 μmol) in acetonitrile (0.6 mL). The mixture was 
azeotropically dried with 3 sequential additions of acetonitrile (1.6 mL total) at 90 °C under 
nitrogen.  
[
18
F]FPCA  
[
18
F]FPCA was produced as per the methodology described by Morris et al 
[11]
. In short, 3-
carboxaldehyde-N,N,N-trimethylpyridine-2-aminium bromide (2 mg, 8 μmol) in DMSO 
(200 μL) was added to the reactor containing azeotropically dried [18F]fluoride and heated to 
70°C for 10 min. [
18
F]FPCA was trapped and washed on an AFFINIMIP
® 
(AFFINISEP, 
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France)
 
2.0 mL solid phase extraction (SPE) cartridge. Elution of [
18
F]FPCA was achieved 
using methanol (3 mL) into the reactor followed by solvent evaporation under vacuum at 
60°C for 6.5 min. Synthesis of the 3-carboxaldehyde-N,N,N-trimethylpyridine-2-aminium 
bromide precursor is described elsewhere 
[11]
.  
[
18
F]FPCA-F9 solution 
A mixture of (Aoa)F9 (1.5 mg, ~880 nmol), anilinium hydrochloride (2.6mg, 20 μL) and 
gentisic acid (sodium salt hydrate, 1 mg) in citric acid (0.02 M, 250 μL) was added to 
purified and dried [
18
F]FPCA (pH 2.7). The reaction mixture was heated to 70 °C for 
30 minutes and purified using a TSK-gel® SE-HPLC column (7.5mm ID x 30 cm, 10 μm, 
Hichrom Tosoh Bioscience, Berkshire UK) eluted with PBS with 1 % ascorbic acid / 
1mL/min, tR = 10 minutes and analysed for quality control purposes using size exclusion-
HPLC (SE-HPLC) (Superdex peptide 10/300 GL, PBS, 1 mL/min, 220 nm, tR 
= 18.05 minutes). The final concentration of the solution was 0.3 mM.  
[
18
F]FPCA-F9 hydrogel 
[
18
F]FPCA-F9 was prepared as described above. [
18
F]FPCA-F9 hydrogel was prepared by 
adding a small amount of [
18
F]FPCA-F9 to an unlabelled, unfunctionalised F9 hydrogel. In 
short, unfunctionalised F9 (11.6 mg) in H2O (440 μL) was sonicated for 15 minutes before 
addition of 120 μL (411 nM) of purified [18F]FPCA-F9 in PBS solution. The mixture was 
vortexed and the pH adjusted to 5.5 using NaOH (0.5 M) and the final volume increased to 
600 μL using H2O giving a final hydrogel concentration 0.01M.  
Fluorescence preparation  
FITC-F9 hydrogel 
FITC-F9 hydrogel was prepared using the same procedure as described above. 
Unfunctionalised F9 (10.5 mg) in H2O (440 μL) was sonicated for 15 minutes before addition 
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of FITC-labelled F9 (1.2 mg) in DMSO (5 μL). The mixture was sonicated for a further 15 
minutes and the pH adjusted to 5.5 using NaOH (0.5 M). The final volume was increased to 
491.5 μL using deionised H2O giving, once again, a final hydrogel concentration of 0.01M.  
Pre-clinical analyses 
All animal handling was in accordance with UK legislation under the 1986 Animals 
(Scientific Procedures) Act. 
Pre-clinical PET [
18
F]FPCA-F9 solution & hydrogel 
C3H mice were anaesthetised using isoflurane induction 4 % and maintained 1.5 % in 70 % 
N2O and 30 % O2 mixture. [
18
F]FPCA-F9 solution was injected in the tail vein (13 MBq, 
n=4) of healthy mice or [
18
F]FPCA-F9 hydrogel was injected subcutaneously into the right 
flank of different healthy mice (2-5 MBq, n=3). The acquisition protocol parameters 
consisted of a preliminary CT scan to determine attenuation correction factors followed by a 
1 and 4 hour PET acquisition time for [
18
F]FPCA-F9 solution and hydrogel respectively. 
Major excretory organs, including liver, kidney and bladder as well as bone and hydrogel 
region (in [
18
F]FPCA-F9 hydrogel scans only), were delineated on CT and uptake was 
quantified as SUV.  
[
18
F]FPCA-F9 pre-clinical metabolite analysis 
Plasma, kidney and urine samples were taken post-sacrifice at 5 (n=2) and 20 (n=2) minutes 
post injection of [
18
F]FPCA-F9 monomer. Plasma was extracted from whole blood samples 
using a Thermo ALC multispeed refrigerated centrifuge PK121R (8720 g, 4 °C for 3 
minutes). Kidney samples were homogenised, centrifuged (8720 g, 4 °C for 3 minutes) and 
the supernatant removed for HPLC analysis. Urine samples were directly injected onto HPLC 
without sample preparation using a GE Superdex peptide 10/300 GL (GE Healthcare, UK) 
eluted with PBS (1 mL/min, 220 nm). 
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In vivo fluorescence analysis 
C3H mice (n = 2) were anaesthetised using isoflurane (induction 4 % and maintained 1.5 %) 
in 70 % N2O and 30 % O2 mixture. FITC-F9 gel (200 μL) was injected subcutaneously into 
the right flank (C3H mice) and fluorescence data attained over 5 days using a 30 second 
acquisition time. Relative bioluminescent counts were normalised to acquisition time and 
quantified in units of counts.  Excitation and emission wavelengths 487 and 547 nm 
respectively, FLI integration at 400 ms per frame, BVR pixel 171 μm with a pixel size of 170 
x 170 μm. Hydrogel site was delineated and emission was quantified as counts per minute. 
Results and Discussion  
[
18
F]FPCA-F9 radiochemistry 
The radiochemical conversion of (Aoa)F9 to [
18
F]FPCA-F9 by reaction with [
18
F]FPCA was 
63 ± 7 % and 400 ± 200  MBq of [
18
F]FPCA-F9 were produced (decay-corrected from end of 
bombardment) starting with 25-30 GBq of [
18
F]fluoride (n=6). Radiosynthesis of [
18
F]FPCA-
F9 as a solution and a hydrogel was completed within 2 hours from end of bombardment.   
Figure A of supplementary material provides GE TRACERlab FX-FN trace for crude 
reaction mixture. Radiochemical purity of [
18
F]FPCA-F9 >98  % was attained, as can be seen 
in Figure B of supplementary material. [
18
F]FPCA-F9 radiochemical yields (RCY) were not 
reflective of the high radiolabelling efficiency of (Aoa)F9 with [
18
F]FPCA, due to significant 
product loss during the automated radiosynthesis. This was attributable to the agglutinative 
nature of the peptide and issues of poor solubility and high viscosity of (Aoa)F9, despite 
using low concentrations; this caused handling difficulties for the automated platform due to 
the platform’s narrow-bore tubing. Notwithstanding, [18F]FPCA-F9 was produced in 
sufficient quantities for use in PET analysis. It is anticipated that use of larger-bore tubing 
and the ability to transfer the reaction mixture across the platform using a syringe drive, as 
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opposed to a helium flow, which is slow and controlled might improve recovery of 
[
18
F]FPCA-F9.  However, the uniquely aggregative nature of the hydrogel-forming peptide 
precludes its comparison with other [
18
F]FPCA peptide radiolabelling.   
 [
18
F]FPCA-F9 solution biodistribution - PET 
The PET images in Figure 2 A, B and C depict [
18
F]FPCA-F9 biodistribution at 60 seconds, 
15 minutes and 1 hour post injection respectively.  Figure 2D shows the uptake of 
[
18
F]FPCA-F9 over 60 minutes in key organs. Kidney uptake was observed within 5 minutes 
post injection (5.9 ± 1.9 SUV).  
This was followed by significant bladder accumulation, as clearly seen in Figures 2B and C, 
which begins to plateau after 20 minutes (53.4 ± 16.6 SUV). Liver uptake remained low over 
the time course of the scan (1.4 ± 0.1 and 0.7 ± 0.1 SUV at 5 and 20 minutes post injection 
respectively). The concentrations observed within the liver were consistently lower than those 
seen in the kidney whilst the highest concentration were seen in the bladder; confirming that 
the kidney is the major excretory organ for [
18
F]FPCA-F9 and potential radiometabolite(s). 
Rapid renal excretion is expected of unmodified, small peptides 
[12, 13]
.  
Gradual bone accumulation can also be seen (7.8 ± 2.5 SUV 1 hour post injection), although 
levels of radioactivity are overshadowed by much higher concentrations in the bladder (47.4 
± 7.2 SUV 1 hour post injection); bone uptake was most notable at regions of the joint. 
Accumulation of radioactivity in the bone can be ascribed either to defluorination of 
[
18
F]FPCA-F9 or to the interaction of the peptide with the bone tissue. Bone uptake followed 
kidney uptake, an organ which has been previously implicated in defluorination 
[14, 15]
; 
however no free [
18
F]fluoride was observed in metabolic analyses (discussed later) we 
cannot, therefore, exclude the possibility of an interaction between a positively charged 
[
18
F]FPA-F9 (at physiological pH) and negatively charged protein rich cartilage tissue.  
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This potential interaction is currently being investigated in our laboratory and is outside the 
scope of this article.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: [
18
F]FPCA-F9 solution at A) 60 seconds,  B) 15 minutes and C) 1 hour post 
injection and D) TAC [
18
F]FPCA-F9 biodistribution in bone and excretory organs 
(C3H mice, n=4) 
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 [
18
F]FPCA-F9 solution metabolite analysis 
Liver, kidney, urine and plasma samples were analysed using SE-HPLC to quantify the 
degree of metabolic degradation of the peptide. The analysis identified the major peak as 
[
18
F]FPCA-F9 with a retention time of ~18 minutes; none of the samples analysed showed 
any metabolite of [
18
F]FPCA-F9 (see Supplementary Material Figure C). Table 1 shows the 
percentage of parent compound ([
18
F]FPCA-F9) identified in each of the samples after 60 
minutes. The high percentage of parent compound in all samples demonstrates the high 
stability of [
18
F]FPCA-F9.  
Liver and kidney samples, though, showed a second peak at ~8 minutes accounting for ~5 % 
of the radioactivity (see Supplementary Material Figure Cii). Urine samples showed a peak 
with a retention time of ~12 minutes, accounting for 5 % of the radioactivity (see 
supplementary Figure Ciii) alongside the [
18
F]FPCA-F9 peak. A shorter retention time is 
suggestive of a larger species than [
18
F]FPCA-F9, conceivably a result of [
18
F]FPCA-F9 
aggregation or interaction with a large molecular weight protein. As discussed above, 
[
18
F]FPCA-F9 carries a positive charge under physiological conditions and can therefore 
interact with negatively charged proteins. The large molecular weight radiolabelled species 
seen in both liver and kidney samples (tR ~8 minutes), falls outside the exclusion limit of the 
column (V0 ~9 minutes) therefore suggestive of molecular mass >12 kDa. The species in the 
urine sample (tR 12.5 minutes) is likely, according to molecular weight standard analysis, to 
have a molecular mass between 8 and 10 kDa.  
The absence of radiolabelled species with a molecular mass smaller than that of [
18
F]FPCA-
F9 and within the 22.5 minute column exclusion limit is suggestive of the absence of 
[
18
F]FPCA-F9 radiometabolites, including [
18
F]fluoride. The absence of a [
18
F]fluoride 
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radiometabolite provides evidence against [
18
F]FPCA-F9 defluorination and further supports 
the notions of an interaction between F9 and the cartilage. 
 
If [
18
F]FPCA-F9 is aggregating with circulating proteins, similar aggregation is expected to 
be observed in plasma sample, which is not the case. The TAC shows that F9 is rapidly 
transported to the kidneys, thereby minimising the time for which F9 can interact with 
circulating proteins such as albumin in the plasma.  
Table 1: Quantification of parent ([
18
F]FPCA-F9) fraction after 60 minutes (data expressed 
as mean ± SD,  n=4)  
Liver Kidney Urine Plasma 
94 ±0 % 95 ±1 % 95 ±1 % 100   
 
Importantly, [
18
F]FPCA-F9 showed high plasma stability according to metabolite analysis 
and is rapidly and predominantly excreted by the kidney; thereby showing a favourable 
biodistribution profile for the use of F9 as a biomaterial.  
[
18
F]FPCA-F9 hydrogel biodistribution - PET 
[
18
F]FPCA-F9 hydrogel was injected subcutaneously into the flank of C3H mice; its in vivo 
behaviour over a 4 hour time-course can be interpreted from Figure 3. Figures 3 A and B (60 
seconds and 4 hours post injection) clearly show the radiolabelled hydrogel. Figure 3C 
provides the biodistribution of [
18
F]FPCA-F9 peptide in the bone and excretory organs. The 
increasing concentrations of [
18
F]FPCA-F9 in the kidneys and bladder clearly show that the 
peptide is gradually being eluted from the hydrogel as the latter physically degrades / 
disaggregates.  
A progressive increase in radioactivity over 150 minutes is observed in the bladder, before 
plateauing (17.4 ± 1.3 SUV). Although this is reminiscent of the excretion profile of the 
peptide solution, albeit over a different time period, there is a two-step profile for bladder 
  
This article is protected by copyright. All rights reserved. 
accumulation that was observed in all mice. This is anticipated to be as a result of the staged 
non-uniform disaggregation of the hydrogel; smaller and more vulnerable hydrogel fragments 
at the periphery are expected to disaggregate first and rapidly before the bulk of the hydrogel.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3: [
18
F]FPCA-F9 hydrogel at A) 60 seconds and  B) 4 hours post 
injection C) TAC showing [
18
F]FPCA-F9 biodistribution in bone and excretory 
organs (C3H mice, n=3) 
 
 
 
A B 
C  
 
bladder 
hydrogel 
joints 
bladder 
hydrogel 
  
This article is protected by copyright. All rights reserved. 
Bone uptake of [
18
F]FPA-F9 was also observed (3.8 ± 1.3 SUV 1 hour post injection) in this 
case and can be seen in Figure 3. Uptake of [
18
F]FPCA-F9 in the kidney, bladder and liver, 
major excretory organs, (1.15  ± 0.2, 5.9  ± 3.8 and 0.4 ± 0.1 SUV respectively, 20 minutes 
post injection) and also shown in Figure 3C. Akin to when [
18
F]FPCA-F9 was administered 
as a solution, liver uptake remained below the levels observed in the kidney and significantly 
below bladder levels and this was true over the duration of the experiment (0.7 ± 0.1 SUV at 
20 minutes post injection). The work confirms that the peptide exhibited the projected 
biodistribution with no significant changes in its in vivo behaviour, on account of its gelation. 
FITC-F9 hydrogel - fluorescence imaging 
Despite the inability to detect FITC-F9 penetration into the tissue, as a consequence of the 
limitations imposed by FITC emission, shallow injection of FITC-F9 produced fluorescence 
data that was a good indicator of the hydrogel biological half-life. The intention of using BLI 
as a complementary technique was to help visualise the process of hydrogel expansion and 
disaggregation; this data was used to augment PET data which was used to provide 
information regarding biodistribution and route of F9 metabolism. 
Fluorescence data is presented in Figure 4, the data shows FITC-F9 hydrogel 60 seconds, 48 
and 96 hours post injection (Figure 4 A, B and C respectively)  in the flank of C3H mice 
(n=2).  
Qualitative analysis of the preliminary data permits a first appreciation of the results. Signal 
intensity, corresponding to FITC-F9, was measured over the course of 5 days, beginning at 
the time of injection. Steady depletion in signal intensity was observed, with a 43 ± 8 % 
reduction over the first 24 hours and 60 ± 3 % over 96 hours, attributable to disaggregation of 
the hydrogel over time. Results of the fluorescence work, therefore, suggest an F9 hydrogel 
biological half-life between 1 and 4 days.  
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An expansion of ~10 % was observed over the first 24 hours, which dropped to ~3 % over 48 
hours. These results suggest that, post injection, there is further penetration of the hydrogel in 
the surrounding tissues. These hydrogels are known to be shear thinning and animal 
movement will promote gel tissue penetration. This is then followed by the slow 
disaggregation of the hydrogel. 
 
 
 
 
 
The fluorescence data, despite not being fully quantitative, are in agreement with PET data 
providing evidence for the exploitable in vivo life-time of F9 hydrogels as a biomaterial for 
either tissue engineering or drug delivery applications. 
Conclusion 
We report the automated synthesis of a radiolabelled gel-forming peptide, [
18
F]FPCA-F9, and 
its pre-clinical PET analysis alongside preliminary fluorescence imaging data; this permitted 
in vivo characterisation of its behaviour.  Pre-clinical results demonstrated renal excretion as 
the major elimination route for labelled-F9 monomer, both after administration as a solution 
and a hydrogel. Results also showed the high plasma stability of the labelled-F9 monomers 
and established a favourable biological half-life of labelled-F9 hydrogel. The current work 
has confirmed that the behaviour exhibited by F9 is typical of natural, small peptides 
[12]
 and 
its in vivo biodistribution is not altered on account of its gel-form. 
 
ROI 488e3 
counts
ROI 266e3 
counts
ROI 183e3 
counts
A B C
Figure 4: Fluorescence imaging of FITC-F9 hydrogel A) 60 seconds, B) 48 hours and 
C) 96 hours post injection 
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Collectively, the fluorescence and PET data provide insight into a possible in vivo pathway 
for F9 hydrogel; firstly characterised by hydrogel tissue penetration followed by 
disaggregation and final elimination via renal excretion. Due to the natural amino acid 
composition of F9 alongside its in vivo metabolic profile, F9 is not expected to have issues of 
toxicity 
[16]
. Such characteristics would highlight F9 hydrogel as ideal biomaterial that could 
be used as a silent carrier for localised drug-delivery. This is of particular importance in 
oncological applications wherein targeted drug delivery helps to ensure maximal drug dose at 
the tumour whilst minimising drug delivery to non-target sites.  
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